QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced the regulatory approval of its therascreen ® EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, ...
Company will work with ImClone and BMS to develop FDA-approved test for mCRC patients. DxS is to work with ImClone Systems and Bristol-Myers Squibb on the development of a companion diagnostic for the ...
LOS ANGELES, Oct. 3, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted approval for EntroGen's CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix® ...
Testing for genetic mutations has long been complicated, expensive, time-consuming, and, in some parts of the world, inaccessible. Dr. Pierre Billon, an assistant professor at the University of ...
Assures 100x upgraded detection sensitivity compare to ddPCR Higher the possibility of precision medicine in the 1st and 2nd stages of cancer patients SEOUL, South Korea--(BUSINESS WIRE)--GENECAST, ...
DxS has announced that lung cancer patients who have acquired gene mutations associated with resistance to tyrosine kinase inhibitors such as Iressa or Tarceva can be identified accurately using a ...
The US Food and Drug Administration (FDA) has granted approval for EntroGen's CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab), a targeted therapy used in the ...
GENECAST, cancer diagnostics company through liquid biopsy, today announced the launch of ADPS TM BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity for Research Use Only (RUO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results